期刊文献+

加味益胃升阳汤联合DOF方案治疗晚期胃癌的临床效果 被引量:3

Clinical effect of modified Yiwei Shengyang decoction combined with DOF regimen in the treatment of advanced gastric cancer
下载PDF
导出
摘要 目的观察加味益胃升阳汤联合DOF方案治疗晚期胃癌的临床效果。方法选取2018年2月至2020年2月我院收治的90例晚期胃癌患者,随机将其分为对照组(45例)与研究组(45例)。对照组给予DOF治疗,研究组在对照组基础上联合加味益胃升阳汤治疗。比较两组患者治疗前、后中医症状积分、免疫功能、临床疗效及毒副反应发生情况。结果治疗前,两组患者的食欲、胃脘疼痛、恶心呕吐、腹泻症状积分,CD3+、CD4+及CD8+比较,差异无统计学意义(P>0.05)。治疗后,两组食欲、胃脘疼痛、恶心呕吐、腹泻症状积分均低于治疗前,且研究组低于对照组,差异具有统计学意义(P<0.05)。治疗后,研究组CD3+、CD4+高于对照组,CD8+低于对照组,差异具有统计学意义(P<0.05)。研究组的治疗总有效率高于对照组,差异具有统计学意义(P<0.05)。研究组的白细胞下降、血小板下降、恶心呕吐、腹泻、口腔炎发生率略低于对照组(P>0.05)。结论加味益胃升阳汤联合DOF方案治疗晚期胃癌患者的效果良好,可降低患者中医症状积分,改善免疫功能,减轻化疗毒副反应。 Objective To observe the clinical effect of modified Yiwei Shengyang decoction combined with DOF regimen in the treatment of advanced gastric cancer.Methods A total of 90 patients with advanced gastric cancer admitted in our hospital from February 2018 to February 2020 were selected and randomly divided into control group(45 cases)and study group(45 cases).The control group was treated with DOF,and the study group was treated with modified Yiwei Shengyang decoction on the basis of the control group.The TCM symptom scores,immune function before and after treatment,clinical efficacy and toxic and side effects were compared between the two groups.Results Before treatment,there were no significant differences in the scores of appetite,epigastric pain,nausea and vomiting,diarrhea symptom,CD3+,CD4+and CD8+between the two groups(P>0.05).After treatment,the scores of appetite,epigastric pain,nausea and vomiting,diarrhea in the two groups were lower than those before treatment,and those in the study group were lower than the control group,and the differences were statistically significant(P<0.05).After treatment,CD3+and CD4+in the study group were higher than those in the control group,and CD8+was lower than that in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment of the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).The incidences of leukopenia,thrombocytopenia,nausea and vomiting,diarrhea and stomatitis in the study group were slightly lower than those in the control group(P>0.05).Conclusion Modified Yiwei Shengyang decoction combined with DOF regimen in the treatment of patients with advanced gastric cancer has a good effect,it can reduce the TCM symptom scores,improve the immune function,and reduce the toxic and side effects of chemotherapy.
作者 刘国义 LIU Guoyi(Oncology Department,Traditional Chinese Medicine Hospital of Linzhou,Anyang 456550,China)
出处 《临床医学研究与实践》 2021年第4期135-137,共3页 Clinical Research and Practice
关键词 加味益胃升阳汤 DOF方案 晚期胃癌 modified Yiwei Shengyang decoction DOF regimen advanced gastric cancer
  • 相关文献

参考文献9

二级参考文献79

  • 1无.胃癌规范化诊疗指南(试行)[J].中国医学前沿杂志(电子版),2013,5(8):56-63. 被引量:341
  • 2杨莹莹,吴会超,穆媛媛,苏薇.胃泌素及其受体拮抗剂对人胃癌细胞株MKN45增殖及TFF1、TFF3表达的影响[J].肿瘤防治研究,2014,41(6):545-548. 被引量:10
  • 3周际昌.实用肿瘤内科学[M]北京:人民卫生出版社,2003591-592.
  • 4Ajani J. Clinical update on an international phase Ⅱ/Ⅲ docetaxel trial(TAX325)[A].2002.
  • 5Ajani JA,Fodor MB,Tjul and in SA. Phase Ⅱ multiinstitutional randomized trial of docetaxel plus cisplatin with or with out fluorouracil in patients with untreated,advanced gastric,orgastroesophageal[J].Journal of Clinical Oncology,2005,(24):5660-5667.
  • 6Bang YJ,Kang WK,Kang YK. Docetaxel 75mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer:a phase Ⅱ trial[J].Japanese Journal of Clinical Oncology,2002,(07):248-254.doi:10.1093/jjco/hyf057.
  • 7Van Cutsem E,Moiseyenko VM,Tjul and in S. Phase Ⅲstudy of docetaxel and cisplatin plus fluorouracil compared with cisplat in and fluorouracil as first line therapy for sdvanced gastric cancer:a report of the V325 Study Group[J].Journal of Clinical Oncology,2006,(31):4991-4997.doi:10.1200/JCO.2006.06.8429.
  • 8MaiM,Sakata Y,Kanamaru R. A late phase Ⅱ clinical study of RP56976 (docetaxel) in patients with advanced or recur rent gastric cancera cooperative study group trial(group B)[J].Japanese Journal of Cancer and Chemotherapy,1999,(04):487-496.
  • 9Graziano F,Catalano V,Baldel liAM. A phase Ⅱ study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer[J].Annals of Oncology,2000.1263-1266.
  • 10Bang YJ,Kang WK,Kang YK. Docetaxel 75mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer.a phase Ⅱ trial[J].Japanese Journal of Clinical Oncology,2002.248-254.

共引文献121

同被引文献102

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部